Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Marksans Pharma Limited ( (IN:MARKSANS) ) has provided an announcement.
Marksans Pharma Limited announced that its UK-based wholly owned subsidiary, Relonchem Limited, has received Marketing Authorization from the UK MHRA for its Mefenamic Acid 250 mg and 500 mg Film-Coated Tablets. This authorization is expected to enhance Marksans Pharma’s market presence in the UK and potentially boost its operational capabilities and market positioning in the pharmaceutical industry.
More about Marksans Pharma Limited
Marksans Pharma Limited, headquartered in Mumbai, India, is involved in the research, manufacturing, and marketing of generic pharmaceutical formulations globally. The company operates manufacturing facilities in India, USA, and UK, which are approved by regulatory agencies such as USFDA, UKMHRA, and Australian TGA. Its product portfolio covers major therapeutic segments including cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterological, and anti-allergies.
Average Trading Volume: 94,446
Technical Sentiment Signal: Hold
Current Market Cap: 87.32B INR
See more insights into MARKSANS stock on TipRanks’ Stock Analysis page.